Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: PAVmed is a multi-product life sciences company operating as a parent entity for distinct subsidiaries. Key assets include Lucid Diagnostics (EsoGuard test), now accounted for as an equity method investment following deconsolidation in September 2024, and Veris Health (cancer care platform and implantable monitor), a majority-owned consolidated subsidiary. The company operates as a single reportable segment.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
| Metric | Amount (in thousands) |
|---|---|
| Revenue | $19 |
| Operating Loss | $(15,003) |
| Net Income (Loss) Attributable to PAVmed | $1,664 |
| Net Loss Attributable to Common Stockholders | $(1,942) |
| Cash and Cash Equivalents (End of Period) | $3,103 |
| Net Cash Used in Operating Activities | $(3,655) |
| Total Debt (Senior Secured Convertible Notes) | $6,900 (Fair Value) |
| Working Capital Deficiency | ~$(6,300) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $19 thousand from $2,985 thousand in the prior year period. This is primarily due to the deconsolidation of Lucid Diagnostics on September 10, 2024, removing EsoGuard test revenue from consolidated results.
- Expense Reduction: Operating expenses decreased significantly (e.g., Sales & Marketing down from $11.5M to $0.7M; G&A down from $20.3M to $11.6M) due to the exclusion of Lucid's operating costs post-deconsolidation.
- Equity Method Investment: PAVmed recognized an unrealized gain of $6.0 million on its investment in Lucid Diagnostics for the nine months ended September 30, 2025, driven by an increase in Lucid's stock price.
- Debt Restructuring: The April 2022 Senior Convertible Note was satisfied in full via an exchange for Series C Preferred Stock in January 2025. The remaining September 2022 Note has a fair value of $6.9 million.
- Management Fee Income: Increased to $9.45 million (from $0.7 million in the prior year) as fees from Lucid are now fully recognized as income rather than offset by consolidated operating expenses.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for 12 months. This is due to recurring losses, a working capital deficiency of approximately $6.3 million, and reliance on future financing or revenue growth from Veris Health.
- Liquidity Strategy: The company plans to fund operations through management service fees from subsidiaries, increased Veris Health revenues, and additional equity or debt financings.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq minimum bid price requirements ($1.00). It has been granted an extension until January 19, 2026, to regain compliance, potentially via a reverse stock split.
- Debt Covenants: The holder of the Senior Secured Convertible Note has waived financial covenants (including minimum cash and market cap tests) through December 31, 2025.
- Preferred Stock: Series C Preferred Stock includes complex conversion features and "deemed dividends" recognized due to conversion price reductions, which increased net loss attributable to common stockholders.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.1 million cash balance against the $6.3 million working capital deficiency and upcoming debt obligations.
- Debt Maturity: Confirm the status of the September 2022 Senior Convertible Note maturing December 31, 2025, and the terms of the waiver extension.
- Lucid Investment Valuation: Assess the volatility of the $31.6 million equity method investment in Lucid Diagnostics and its impact on net income.
- Series C Preferred Stock: Review the terms of the Series C Preferred Stock, specifically the conversion price reductions and potential dilution to common shareholders.
- Nasdaq Delisting Risk: Monitor the progress of the proposed reverse stock split and the ability to meet the $1.00 bid price requirement by January 2026.